Related Experiment Video
Updated: Jan 31, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors
E Kouvaras1, Z Christoni1, I Siasios1
1a Department of Pathology , Medical School, University of Thessaly , Larisa , Greece.
Abstract:
Neoangiogenesis has been demonstrated in chondrosarcoma. Anti-angiogenic therapies are being tested in clinical trials for chondrosarcomas. Studies of the underlying mechanisms have been performed almost exclusively in cell lines. We immunostained 20 samples of chondrosarcoma and 20 samples of enchondromas with antibodies against hypoxia-inducible factor 1-alpha (HIF-1-alpha) and vascular endothelial growth factor (VEGF). The immunohistochemical staining of HIF-1-alpha and VEGF were highly correlated. Enchondromas were HIF-1-alpha and VEGF negative, whereas all chondrosarcoma exhibited HIF-1-alpha and VEGF immunostaining. HIF-1-alpha/VEGF double positive cases were almost exclusively chondrosarcomas with a high tumor grade. We suggest that HIF-1-alpha is a marker of malignancy in chondrosarcomas that correlates with tumor neo-angiogenesis. Our findings also suggest that a HIF-1-alpha/VEGF angiogenic pathway may exist in chondrosarcoma in vivo as in other malignant tumors. The inclusion of novel inhibitors to HIF-1-alpha and other factors may optimize anti-angiogenic interventions in chondrosarcoma.
Insights
Hypoxia-inducible factor 1-alpha (HIF-1-alpha) and vascular endothelial growth factor (VEGF) are key markers of malignancy in chondrosarcoma, correlating with tumor neo-angiogenesis and potentially guiding anti-angiogenic therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Neoangiogenesis is observed in chondrosarcoma, leading to clinical trials for anti-angiogenic therapies.
- Previous mechanistic studies predominantly utilized cell lines, limiting in vivo understanding.
Purpose of the Study:
- To investigate the expression and correlation of hypoxia-inducible factor 1-alpha (HIF-1-alpha) and vascular endothelial growth factor (VEGF) in chondrosarcoma and enchondroma.
- To assess the potential of HIF-1-alpha as a marker for chondrosarcoma malignancy and its link to tumor neo-angiogenesis.
Main Methods:
- Immunohistochemical staining of 20 chondrosarcoma and 20 enchondroma samples using antibodies against HIF-1-alpha and VEGF.
- Correlation analysis of HIF-1-alpha and VEGF staining patterns between the two tissue types and across tumor grades.
Main Results:
- HIF-1-alpha and VEGF expression were highly correlated in chondrosarcoma samples.
- Enchondromas showed negative staining for both HIF-1-alpha and VEGF, while all chondrosarcomas were positive.
- High tumor grade chondrosarcomas exclusively exhibited double positivity for HIF-1-alpha and VEGF.
Conclusions:
- HIF-1-alpha serves as a marker of malignancy in chondrosarcoma, strongly correlating with tumor neo-angiogenesis.
- A HIF-1-alpha/VEGF angiogenic pathway is suggested to be active in chondrosarcoma in vivo.
- Targeting HIF-1-alpha and related factors may enhance the efficacy of anti-angiogenic treatments for chondrosarcoma.
More Related Videos
05:56Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
Published on: January 22, 2020
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
Related Concept Videos
Transcription Factors
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Factors Affecting Solubility